FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313597904> ?p ?o ?g. }

• W4313597904 endingPage "211" @default.
• W4313597904 startingPage "203" @default.
• W4313597904 abstract "Heart failure (HF) and atrial fibrillation (AF) commonly coexist in real-life clinical practice. Among patients with HF with reduced ejection fraction (HFrEF) or HF with mildly reduced ejection fraction (HFmrEF), guidelines call for evidence-based target doses of renin-angiotensin-aldosterone system inhibitors and beta-blockers. However, target doses of guideline-directed medical treatment (GDMT) are often underused in real-world conditions, including HF-AF comorbidity. This retrospective cohort study of a randomized trial (Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with nonvalvular AF) included hospitalized patients with AF and HFrEF or HFmrEF. Optimally targeted GDMT was defined as intake of evidence-based target doses of renin-angiotensin-aldosterone system and beta-blockers at 3 months after discharge. Rates of optimally targeted GDMT achievement across the baseline estimated glomerular filtration rate (eGFR) were assessed. Independent predictors of nontargeted GDMT and its association with all-cause mortality and the composite of cardiovascular death or HF hospitalization were assessed by regression analyses. In total, 374 patients with AF and HFrEF or HFmrEF were studied. At 3 months after discharge, 30.7% received target doses of GDMT medications. The rate of optimally targeted GDMT was reduced by 11% for every 10 mg/min/1.73 m 2 decrease in baseline eGFR [adjusted β = 0.99; 95% confidence interval (CI), 0.98-0.99] levels. After a median 31-month follow-up period, 37.8% patients in the optimally targeted GDMT group died, as compared with 67.8% (adjusted hazard ratio: 1.49; 95% CI, 1.05-2.13) in the nontargeted GDMT group. The risk of cardiovascular death or HF hospitalization was also higher in these patients (adjusted hazard ratio: 1.60; 95% CI, 1.17-2.20). Target doses of all HF drugs were reached in roughly one-third of patients with AF and HFrEF or HFmrEF 3 months after hospital discharge. Nontargeted GDMT was more frequent across lower eGFR levels and was associated with worse outcomes." @default.
• W4313597904 created "2023-01-06" @default.
• W4313597904 creator A5004790580 @default.
• W4313597904 creator A5011702912 @default.
• W4313597904 creator A5022021799 @default.
• W4313597904 creator A5027931915 @default.
• W4313597904 creator A5031131640 @default.
• W4313597904 creator A5037016137 @default.
• W4313597904 creator A5045803379 @default.
• W4313597904 creator A5048185342 @default.
• W4313597904 creator A5053464595 @default.
• W4313597904 creator A5074737994 @default.
• W4313597904 creator A5075289237 @default.
• W4313597904 creator A5076564833 @default.
• W4313597904 creator A5080783494 @default.
• W4313597904 creator A5081187397 @default.
• W4313597904 creator A5089835863 @default.
• W4313597904 creator A5091375386 @default.
• W4313597904 date "2023-03-01" @default.
• W4313597904 modified "2023-10-11" @default.
• W4313597904 title "Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial" @default.
• W4313597904 cites W1532211562 @default.
• W4313597904 cites W1968782440 @default.
• W4313597904 cites W1969817339 @default.
• W4313597904 cites W2002917601 @default.
• W4313597904 cites W2038065774 @default.
• W4313597904 cites W2044136105 @default.
• W4313597904 cites W2044867903 @default.
• W4313597904 cites W2074758594 @default.
• W4313597904 cites W2081730623 @default.
• W4313597904 cites W2093935755 @default.
• W4313597904 cites W2105138814 @default.
• W4313597904 cites W2112643874 @default.
• W4313597904 cites W2114720835 @default.
• W4313597904 cites W2133449415 @default.
• W4313597904 cites W2152094259 @default.
• W4313597904 cites W2178738676 @default.
• W4313597904 cites W2219280845 @default.
• W4313597904 cites W2338332677 @default.
• W4313597904 cites W2344609016 @default.
• W4313597904 cites W2381016711 @default.
• W4313597904 cites W2427094903 @default.
• W4313597904 cites W2592176942 @default.
• W4313597904 cites W2745438221 @default.
• W4313597904 cites W2800891490 @default.
• W4313597904 cites W2883756867 @default.
• W4313597904 cites W2908418680 @default.
• W4313597904 cites W2915620466 @default.
• W4313597904 cites W2924113265 @default.
• W4313597904 cites W2926726860 @default.
• W4313597904 cites W2984620797 @default.
• W4313597904 cites W3014414496 @default.
• W4313597904 cites W3019698662 @default.
• W4313597904 cites W3098344060 @default.
• W4313597904 cites W3120712248 @default.
• W4313597904 cites W3165281062 @default.
• W4313597904 cites W4293085726 @default.
• W4313597904 doi "https://doi.org/10.1097/fjc.0000000000001390" @default.
• W4313597904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36626410" @default.
• W4313597904 hasPublicationYear "2023" @default.
• W4313597904 type Work @default.
• W4313597904 citedByCount "0" @default.
• W4313597904 crossrefType "journal-article" @default.
• W4313597904 hasAuthorship W4313597904A5004790580 @default.
• W4313597904 hasAuthorship W4313597904A5011702912 @default.
• W4313597904 hasAuthorship W4313597904A5022021799 @default.
• W4313597904 hasAuthorship W4313597904A5027931915 @default.
• W4313597904 hasAuthorship W4313597904A5031131640 @default.
• W4313597904 hasAuthorship W4313597904A5037016137 @default.
• W4313597904 hasAuthorship W4313597904A5045803379 @default.
• W4313597904 hasAuthorship W4313597904A5048185342 @default.
• W4313597904 hasAuthorship W4313597904A5053464595 @default.
• W4313597904 hasAuthorship W4313597904A5074737994 @default.
• W4313597904 hasAuthorship W4313597904A5075289237 @default.
• W4313597904 hasAuthorship W4313597904A5076564833 @default.
• W4313597904 hasAuthorship W4313597904A5080783494 @default.
• W4313597904 hasAuthorship W4313597904A5081187397 @default.
• W4313597904 hasAuthorship W4313597904A5089835863 @default.
• W4313597904 hasAuthorship W4313597904A5091375386 @default.
• W4313597904 hasConcept C126322002 @default.
• W4313597904 hasConcept C142724271 @default.
• W4313597904 hasConcept C164705383 @default.
• W4313597904 hasConcept C207103383 @default.
• W4313597904 hasConcept C2778198053 @default.
• W4313597904 hasConcept C2779161974 @default.
• W4313597904 hasConcept C2780182762 @default.
• W4313597904 hasConcept C44249647 @default.
• W4313597904 hasConcept C71924100 @default.
• W4313597904 hasConcept C78085059 @default.
• W4313597904 hasConceptScore W4313597904C126322002 @default.
• W4313597904 hasConceptScore W4313597904C142724271 @default.
• W4313597904 hasConceptScore W4313597904C164705383 @default.
• W4313597904 hasConceptScore W4313597904C207103383 @default.
• W4313597904 hasConceptScore W4313597904C2778198053 @default.
• W4313597904 hasConceptScore W4313597904C2779161974 @default.
• W4313597904 hasConceptScore W4313597904C2780182762 @default.
• W4313597904 hasConceptScore W4313597904C44249647 @default.
• W4313597904 hasConceptScore W4313597904C71924100 @default.

• next